{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:18Z","timestamp":1792496238323,"version":"4.5.0"},"reference-count":118,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2017,1,2]]},"DOI":"10.1080\/14740338.2017.1247807","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T14:10:31Z","timestamp":1476281431000},"page":"27-39","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone\/bupropion extended release and phentermine-topiramate extended release"],"prefix":"10.1080","volume":"16","author":[{"given":"Bruno","family":"Halpern","sequence":"first","affiliation":[{"name":",","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio C.","family":"Mancini","sequence":"additional","affiliation":[{"name":",","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2009.01.009"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1530"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2028"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021423"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-1-200707030-00007"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-7-201110040-00006"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00271-3"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3415"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.995088"},{"key":"e_1_3_3_12_1","article-title":"Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes","volume":"11","author":"Neff KJ","year":"2013","unstructured":"Neff KJ, Olbers T, Le Roux CW. Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. BMC Med. 2013;11:8.","journal-title":"BMC Med"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0004"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20120223"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12299"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph3082398"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.028381"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350180055008"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1342"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70678"},{"key":"e_1_3_3_27_1","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine an placebo in obese subjects on an energy restricted diet. A double-blind trial","volume":"16","author":"Astrup A","year":"1992","unstructured":"Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine an placebo in obese subjects on an energy restricted diet. A double-blind trial. Int J Obes Relat Metab Disord. 1992;16:269\u2013277.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432502"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1504267"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.69"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.53"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.09.006"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802707"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.461"},{"issue":"8","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1358\/dot.2011.47.8.1617339","article-title":"Bupropion\/naltrexone fixed-dose combination for the treatment of obesity","volume":"47","author":"Halpern B","year":"2011","unstructured":"Halpern B, Faria AM, Halpern A. Bupropion\/naltrexone fixed-dose combination for the treatment of obesity. Drugs Today 2011 (Barc). 2011;47(8):575\u2013581.","journal-title":"Drugs Today 2011 (Barc)"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.86"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903048959"},{"issue":"10","key":"e_1_3_3_38_1","first-page":"1117","article-title":"Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity","volume":"10","author":"Padwal R","year":"2009","unstructured":"Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs. 2009;10(10):1117\u20131125.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21094"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12657"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.909405"},{"issue":"9","key":"e_1_3_3_45_1","first-page":"395","article-title":"Bupropion: a review of its mechanism of antidepressant activity","volume":"56","author":"Ascher JA","year":"1995","unstructured":"Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395\u2013401.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_46_1","unstructured":"Wood S FDA declines approval for Contrave diet drug; asks for CVD outcomes studies. 2011 Feb 1 [cited 2016 Jun 29]. Available from: http:\/\/www.medscape.com\/viewarticle\/736616"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1558"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.72"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1461"},{"issue":"7","key":"e_1_3_3_51_1","first-page":"256","article-title":"Seizures and bupropion: a review","volume":"50","author":"Davidson J","year":"1989","unstructured":"Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989;50(7):256\u2013261.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.131534"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181dbe1b4"},{"issue":"7","key":"e_1_3_3_54_1","first-page":"262","article-title":"Treatment of bulimia with bupropion: a multicenter controlled trial","volume":"49","author":"Horne RL","year":"1988","unstructured":"Horne RL, Ferguson JM, Pope HG Jr., et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988;49(7):262\u2013266.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.969372"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.41"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.790"},{"issue":"5","key":"e_1_3_3_58_1","article-title":"Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion","volume":"12","author":"Wightman DS","year":"2010","unstructured":"Wightman DS, Foster VJ, Krishen A, et al. Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Prim Care Companion J Clin Psychiatry. 2010;12(5):pii:PCC.09m00894.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327112450901"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0801733"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"e_1_3_3_62_1","unstructured":"US Food and Drug Administration. FDA approves weight-management drug Contrave. [cited 2016 Jun 29] Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm413896.htm"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.2180"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123682"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.94"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01242.x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000145"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2009.07.014"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.74"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-4-5"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(96)80036-7"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00846.x"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.102"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.206"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2008.00041.x"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1272"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.13.13"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60518-7"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0930"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1211277"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802783"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x"},{"key":"e_1_3_3_88_1","doi-asserted-by":"crossref","unstructured":"Posner K Brent D Lucas C et al. Columbia-Suicide Severity Rating Scale (C-SSRS). [cited 2016 Jun 29]. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/slides\/2007-4306s1-01-CU-Posner_files\/frame.htm","DOI":"10.1037\/t52667-000"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.028381"},{"key":"e_1_3_3_90_1","unstructured":"Drug Enforcement Administration: drug fact sheets. [cited 2016 Jun 29]. http:\/\/www.justice.gov\/dea\/druginfo\/concerns.shtml"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181d070d7"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/30.8.599"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112440514"},{"key":"e_1_3_3_94_1","unstructured":"FDA. Statistical review and evaluation: antiepileptic drugs and suicidality. 2008 [cited 2016 Jun 29]. Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4372b1-01-FDA.pdf"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmh.13.4.102"},{"issue":"3","key":"e_1_3_3_96_1","first-page":"A205","article-title":"Topiramate and nephrolithiasis","volume":"36","author":"Wasserstein A","year":"1995","unstructured":"Wasserstein A, Reife R, Rak I. Topiramate and nephrolithiasis. Epilepsia. 1995;36(S3;S153):A205.","journal-title":"Epilepsia"},{"issue":"6","key":"e_1_3_3_97_1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/bcp.12283","article-title":"Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review","volume":"77","author":"Dell\u00b4Orto VG","year":"2014","unstructured":"Dell\u00b4Orto VG, Belotti EA, Goeggel-Simonetti B, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77(6):958\u2013964.","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12480"},{"issue":"3","key":"e_1_3_3_99_1","first-page":"S153","article-title":"Nephrolithiasis during treatment with topiramate","volume":"36","author":"Wasserstein AG","year":"1995","unstructured":"Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia. 1995;36(Suppl 3):S153.","journal-title":"Epilepsia"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1089\/089277902753752188"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.08.003"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.23357"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S43403"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.10.3"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.11.012"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.5186"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S27695"},{"key":"e_1_3_3_108_1","unstructured":"Lorcaserin and phentermine safe combo in weight-loss trial. Medscape Medical News. [cited 2016 Jun 29]. Available from: http:\/\/www.medscape.com\/viewarticle\/834676"},{"key":"e_1_3_3_109_1","unstructured":"clinicaltrials.gov. Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants. [cited 2016 Jun 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02243202"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3956-x"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61525-1"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60432-3"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20122"},{"key":"e_1_3_3_115_1","unstructured":"clinicaltrials.gov. Safety and Efficacy Study of Tesofensine\/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus. [cited 2016 Jun 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02737891?term=tesofensine+metoprolol&rank=1"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.46"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2012.01.001"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03339961"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281501"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2017.1247807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T01:06:44Z","timestamp":1770944804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2017.1247807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,2]]}},"alternative-id":["10.1080\/14740338.2017.1247807"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2017.1247807","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}